ARHGEF6

Across TCGA pan-cancer cohorts, ARHGEF6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF6 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher ARHGEF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

READ, KIRP, and UCEC are the cancer types where ARHGEF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	33	view →
KIRP	OS	Median	All	0.184	0.885	<.001	15	view →
UCEC	OS	Median	II,III,IV	0.860	0.453	.032	10	view →
SKCM	OS	Median	III,IV	1.000	0.686	.019	3	view →
LGG	DFS	Median	All	0.455	0.847	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF6–READ (OS)

Open the READ breakdown →